GeneDx Holdings
- Market cap
- 2.04B
- P/E (TTM)i
- -18.93
- P/Bi
- 8.37
- EPSi
- -0.73
- Div yieldi
- 0.00%
- 52W posi
- 26%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.7 percentage points.
Institutional ownership
- Held by institutions
- 106.04% -2.65pp
- Institutions
- 279 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Corvex Management LP | -- | 16.04% |
| Casdin Capital, LLC | -- | 12.43% |
| Joshua Ruch | Independent Director | 0.52% |
| Jason Ryan | Executive Chair of the Board | 0.40% |
| Katherine Stueland | Chief Executive Officer | 0.39% |
| Richard Pfenniger | Director | 0.15% |
| Kevin Feeley | Senior VP of Operations & CFO | 0.15% |
| Emily Leproust | Independent Director | 0.08% |
| Eli Casdin | Independent Director | 0.08% |
| Keith Meister | Independent Director | 0.08% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Thomas Fuchs | Director | Derivative Exercise and Retained | +1,146 | -- |
| 2026-09-15 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Sale | -10,501 | $94.26–99.00 |
| 2026-09-15 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Retained | +8,249 | -- |
| 2026-09-15 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Sale | -3,728 | $94.26–99.00 |
| 2026-09-15 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Retained | +3,469 | -- |
| 2026-09-08 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Sale | -3,692 | $84.22 |
| 2026-09-08 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Retained | +2,855 | -- |
| 2026-09-08 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Sale | -1,285 | $84.22 |
| 2026-09-08 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Retained | +1,177 | -- |
| 2026-08-31 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Sale | -372 | $83.84 |
| 2026-08-31 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Retained | +345 | -- |
| 2026-06-28 | Mark Gardner | President | Other Derivative Acquisition | +35,441 | -- |
| 2026-06-17 | Rho Capital Partners, Inc. | -- | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Rho Capital Partners, Inc. | -- | Derivative Exercise and Retained | +3,576 | -- |
| 2026-06-17 | Richard Pfenniger | Director | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Richard Pfenniger | Director | Derivative Exercise and Retained | +3,576 | -- |
| 2026-06-17 | Keith Meister | Independent Director | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Keith Meister | Independent Director | Derivative Exercise and Retained | +3,576 | -- |
| 2026-06-17 | Eli Casdin | Independent Director | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Eli Casdin | Independent Director | Derivative Exercise and Retained | +3,576 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:30:23 · For reference only, not investment advice and not tailored to your situation.